Daniel Schmitt is the founder of Actuate Therapeutics. Actuate Therapeutics has raised $28M in total funding. Latest round: IPO.
Daniel Schmitt is the President and Chief Executive Officer of Actuate Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. He joined Actuate in 2015 and led the company through its growth, including its initial public offering on the Nasdaq in 2024.
Full founder directory · Investor directory · Company funding database · Fundraising library